Navigation Links
Experimental Insomnia Drug Shows Promise
Date:11/28/2012

By Amy Norton
HealthDay Reporter

WEDNESDAY, Nov. 28 (HealthDay News) -- A new insomnia drug helped people get a bit more shut-eye in a lab study, researchers report.

The drug, known as suvorexant, is being developed by Merck Research Laboratories, which funded and conducted the study. The medication is not available yet, but the U.S. Food and Drug Administration is reviewing it for possible approval, the researchers said.

In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention. There are sleep aids on the market, but they do not work for everyone and they can have side effects that include sleepwalking, daytime drowsiness and confusion.

Suvorexant works differently from those drugs, zeroing in on specific brain chemicals involved in the ability to sleep, explained study author Dr. William Herring, executive director of clinical research at Merck.

The study, published online Nov. 28 and in the Dec. 4 print issue of the journal Neurology, included 254 healthy adults with primary insomnia, which means it wasn't caused by an underlying physical or mental health problem.

All of the patients spent four weeks on one of four doses of suvorexant and another four weeks on placebo pills. They had their sleep monitored in a sleep lab on their first night with each treatment, and then came back again after four weeks.

Overall, Herring's team found, people slept better with the drug, although the improvement was not dramatic.

At the outset, when patients spent eight hours in bed, they were typically asleep for 66 percent of that time. One day on suvorexant boosted that by anywhere from 5 percent to 13 percent, relative to the placebo. Between 21 and 37 fewer minutes were spent awake during those sleep periods.

There was still a benefit four weeks later. One expert pointed out, however, that the benefit was small.

"The amount of additional sleep was not tremendous," said Dr. Carl Bazil, director of the division of epilepsy and sleep at New York-Presbyterian Hospital/Columbia University Medical Center.

The effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.

But, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake. Standard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.

"The way [suvorexant] works makes a lot of sense," Bazil said. "The hope is that it will help some people who haven't responded to [other drugs], and have fewer side effects."

It's promising news, Bazil added, that there were no serious side effects in this study.

The most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).

There are still many questions, including whether the drug would benefit people with insomnia due to a health condition, which doctors call secondary insomnia.

The study also excluded adults aged 65 or older -- an age group commonly affected by insomnia. But, Herring said, seniors were part of a larger, 12-month trial, and Merck has submitted those results to the FDA.

Another sleep specialist said the findings show "some potential benefit" from suvorexant, but he cautioned insomnia sufferers against relying completely on any drug.

"Medication can be important," said Dr. William Kohler, who directs the Florida Sleep Institute in Spring Hill. "But in the long run, the best methods for treating insomnia are behavioral techniques."

Kohler said cognitive behavioral therapy -- where people learn to change the thoughts and habits that affect their sleep quality -- is a proven way to manage insomnia. For most people, he said, medication should be a temporary treatment; behavior change is the long-term fix.

Bazil agreed: "I look at most people with insomnia as someone who developed bad sleep habits."

A drug, ideally used for a short time, may help encourage sleep and get people on the right track, Bazil said. "But those bad sleep habits -- you've got to address them too," he added.

"The problem," Kohler noted, "is that we don't want to make behavior changes. We want to pop a pill."

More information

Learn more about insomnia and good sleep habits from the National Sleep Foundation.

SOURCES: Carl Bazil, M.D., Ph.D., director, division of epilepsy and sleep, New York-Presbyterian Hospital/Columbia University Medical Center, New York City; William Kohler, M.D., medical director, Florida Sleep Institute, Spring Hill, Fla.; William Herring, M.D., Ph.D., Merck Sharp & Dohme Corp., Whitehouse Station, N.J.; Dec. 4, 2012, Neurology


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Dengue Vaccine Shows Some Success
2. Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
3. Cancer turns off important immune cells, complicating experimental vaccine therapies
4. Experimental Drug May Cut Severe Asthma Attacks: Study
5. Experimental Drug Suppresses Appetite in Mice: Study
6. Experimental Chemical Helps Blind Mice See
7. Experimental drug may extend therapeutic window for stroke
8. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
9. Content Writing King Announces Cancellation Of Experimental Video Creation Process For Their Article Marketing Website
10. Experimental Vaccine Seems to Stop Nicotine Addiction in Mice
11. Experimental drug improves muscle strength among male cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Insomnia Drug Shows Promise
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology: